Azeliragon + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer's Disease
Conditions
Alzheimer's Disease
Trial Timeline
Apr 1, 2015 → Jun 1, 2018
NCT ID
NCT02080364About Azeliragon + Placebo
Azeliragon + Placebo is a phase 3 stage product being developed by vTv Therapeutics for Alzheimer's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT02080364. Target conditions include Alzheimer's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03980730 | Phase 2 | Terminated |
| NCT02080364 | Phase 3 | Terminated |
Competing Products
20 competing products in Alzheimer's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| GSK4527226 | Alector | Phase 2 | 44 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 | Alector | Phase 2 | 44 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| simufilam | Cassava Sciences | Phase 2 | 44 |
| Remternetug + Placebo | Eli Lilly | Phase 3 | 77 |
| solanezumab | Eli Lilly | Phase 2 | 52 |
| LY2886721 + Placebo | Eli Lilly | Phase 1 | 33 |
| Gantenerumab + Gantenerumab + Gantenerumab + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab. | Yuhan | Approved | 85 |
| FK962 | Astellas Pharma | Phase 2 | 52 |
| ASP0777 + Placebo | Astellas Pharma | Phase 1 | 33 |
| Elenbecestat + Placebo | Eisai | Phase 3 | 77 |
| Donepezil | Eisai | Approved | 85 |
| Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg) | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride | Eisai | Phase 3 | 77 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 23 |